biotech-investing argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
biotech-investing argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
biotech-investing argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada
biotech-investing argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
biotech-investing argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
biotech-investing argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia
FDA Accepts LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
FDA Accepts LEQEMBI® IQLIKTM Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
CORRECTION - Domestic Metals Engages ICP Securities Inc. for Automated Market Making Services and provides further details on the engagement of Michael Pound
